Clinical trials: Shingles
Herpes Zoster
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ).
- Trial name
- NCT01827839
- Testing
- Herpes Zoster vaccine (GSK1437173A)
- Where
- 4 sites in Canada, Russia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine
This is a phase I, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of BV211(a herpes zoster vaccine) in Adult Volunteers.
- Trial name
- NCT05718037
- Testing
- Recombinant Zoster Vaccine, Zoster Vaccine Recombinant, Adjuvanted
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Varicella, Influenza Vaccine
Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)
The goal of this clinical trial is to evaluate the immunogenicity of simultaneous administration of varicella live attenuated vaccine (varicella vaccine hereafter) and trivalent inactivated influenza vaccine (TIV hereafter).
- Trial name
- NCT06987942
- Testing
- Varicella vaccine+TIV, Varicella vaccine, TIV
- Where
- China
- Volunteers
- 899 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Varicella
Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
This study will evaluate the immunogenicity, safety, and tolerability of VARIVAX® (Varicella Virus Vaccine Live) manufactured with a new passage extension (PE34) process compared with the VARIVAX® 2016 commercial process.
- Trial name
- NCT03239873
- Testing
- VARIVAX® PE34 Process, VARIVAX® 2016 Commercial Process, M-M-R II®
- Where
- 37 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Shingles
ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)
This study will evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ in Korean adults. Approximately 180 herpes zoster history negative subjects ≥ 50 years of age will be enrolled in the study.
- Trial name
- NCT01556451
- Testing
- Zoster Vaccine Live
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella
A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)
This study will test the immunogenicity, safety, and tolerability of VARIVAX™ manufactured with the Varicella Enhanced Process (VEP) compared with the VARIVAX™ 2007 Process.
- Trial name
- NCT01626794
- Testing
- VARIVAX™ VEP, VARIVAX™ 2007 Process, M-M-R™ II
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to…
- Trial name
- NCT05636436
- Testing
- Low Dose Recombinant Herpes Zoster Vaccine (CHO cells), High Dose Recombinant Herpes Zoster Vaccine (CHO cells), Low dose adjuvant
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Zoster
Study on Efficacy of Attenuated Zoster Vaccine, Live
Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes. Primary infection is manifested as varicella (chickenpox) , whereas reactivation of latent VZV results in a localized eruption known as…
- Trial name
- NCT04334577
- Testing
- live attenuated zoster vaccine
- Where
- 2 sites in China
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Herpes Zoster, Shingles
Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)
This study will determine whether ZOSTAVAX™ made with an alternative manufacturing process [ZOSTAVAX™ (AMP)] is well tolerated and immunogenic, and has a comparable immune response to ZOSTAVAX™.
- Trial name
- NCT01505647
- Testing
- Zoster Vaccine, Live (AMP), Zoster Vaccine, Live
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella
Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus
This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity and safety of a single dose of…
- Trial name
- NCT05460429
- Testing
- Live attenuated varicella vaccine
- Where
- 3 sites in China
- Volunteers
- 37,920 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Varicella, Measles
Safety Study of a Refrigerator-stable Formulation of VARIVAX®
Primary objective: To describe the safety profile of a refrigerator-stable formulation of VARIVAX® as a first single dose injection in 12 to 15 month-old infants in the 42-day follow-up period post-vaccination.
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432731
- Testing
- VARIVAX®, M-M-RTM II
- Where
- 25 sites in France, Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years
Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes.Primary infection is manifested as varicella (chickenpox), whereas reactivation of latent VZV results in a localized eruption known as…
- Trial name
- NCT04072497
- Testing
- One shot of the zoster vaccine, One shot of the varicella vaccine
- Where
- China
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Varicella
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
This study will evaluate the immunogenicity, safety, and tolerability of VARIVAX™ (Varicella Virus Vaccine Live) manufactured with a New Seed Process (NSP) compared with the VARIVAX™ 2007 process.
- Trial name
- NCT02062502
- Testing
- VARIVAX™ New Seed Process, VARIVAX™ 2007 process, M-M-R II™
- Volunteers
- 611 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Rubella, Varicella
Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine
Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals' MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration…
- Conditions
- Rubella, Varicella, Mumps, Measles
- Trial name
- NCT00406211
- Testing
- MMRV, MMR (Priorix®), Varicella (Varilrix®)
- Where
- 41 sites in Austria, Germany
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella (Chickenpox), Varicella Immunisation
Second Dose of Varicella Vaccine in Healthy Children
This study aim to assess the immunogenicity and safety of interchangeable administration of the second dose of varicella vaccine. A total of 300 healthy participants aged 15 months - 12 years will be enrolled.
- Trial name
- NCT07475000
- Testing
- PROVARIX
- Where
- 5 sites in Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Herpes Zoster
Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects
Based on the results of a previous clinical PhaseI/II study, GSK1437173A is the lead GSK candidate Herpes Zoster (HZ) vaccine to prevent episodes of HZ (shingles).
- Trial name
- NCT00434577
- Testing
- Herpes Zoster vaccine GSK1437173A Low Dose, Herpes Zoster vaccine GSK1437173A Medium Dose, Herpes Zoster vaccine GSK1437173A High Dose
- Where
- 11 sites in Czechia, Germany and 2 more
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults
This is a Phase I，randomized, double-blind, placebo controlled,dose escalated,single administrated clinical trial in Chinese healthy adult's volunteers.
- Trial name
- NCT05639803
- Testing
- PEGIFNα1b
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Measles, Mumps
Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines
This study will assess the safety and immunogenicity of ProQuad when administered concomitantly and nonconcomitantly with Tripedia and Comvax.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00984295
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Tripedia, Comparator: Comvax
- Volunteers
- 1,913 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chickenpox
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax.
- Trial name
- NCT06693895
- Testing
- Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine
- Where
- 46 sites in United States, Bulgaria and 6 more
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Shingles
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older
- Trial name
- NCT05304351
- Testing
- Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix
- Where
- 14 sites in United States
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- Curevo Inc